Helmholtz Gemeinschaft


Autoantibodies targeting G protein-coupled receptors: an evolving history in autoimmunity. Report of the 4th international symposium

Item Type:Article
Title:Autoantibodies targeting G protein-coupled receptors: an evolving history in autoimmunity. Report of the 4th international symposium
Creators Name:Cabral-Marques, O. and Moll, G. and Catar, R. and Preuß, B. and Bankamp, L. and Pecher, A.C. and Henes, J. and Klein, R. and Kamalanathan, A.S. and Akbarzadeh, R. and van Oostveen, W. and Hohberger, B. and Endres, M. and Koolmoes, B. and Levarht, N. and Postma, R. and van Duinen, V. and van Zonneveld, A.J. and de Vries-Bouwstra, J. and Fehres, C. and Tran, F. and do Vale, F.Y.N. and da Silva Souza, K.B. and Filgueiras, I.S. and Schimke, L.F. and Baiocchi, G.C. and de Miranda, G.C. and da Fonseca, D.L.M. and Freire, P.P. and Hackel, A.M. and Grasshoff, H. and Stähle, A. and Müller, A. and Dechend, R. and Yu, X. and Petersen, F. and Sotzny, F. and Sakmar, T.P. and Ochs, H.D and Schulze-Forster, Kai and Heidecke, H. and Scheibenbogen, C. and Shoenfeld, Y. and Riemekasten, G.
Abstract:G protein-coupled receptors (GPCR) are involved in various physiological and pathophysiological processes. Functional autoantibodies targeting GPCRs have been associated with multiple disease manifestations in this context. Here we summarize and discuss the relevant findings and concepts presented in the biennial International Meeting on autoantibodies targeting GPCRs (the 4th Symposium), held in Lübeck, Germany, 15-16 September 2022. The symposium focused on the current knowledge of these autoantibodies' role in various diseases, such as cardiovascular, renal, infectious (COVID-19), and autoimmune diseases (e.g., systemic sclerosis and systemic lupus erythematosus). Beyond their association with disease phenotypes, intense research related to the mechanistic action of these autoantibodies on immune regulation and pathogenesis has been developed, underscoring the role of autoantibodies targeting GPCRs on disease outcomes and etiopathogenesis. The observation repeatedly highlighted that autoantibodies targeting GPCRs could also be present in healthy individuals, suggesting that anti-GPCR autoantibodies play a physiologic role in modeling the course of diseases. Since numerous therapies targeting GPCRs have been developed, including small molecules and monoclonal antibodies designed for treating cancer, infections, metabolic disorders, or inflammatory conditions, anti-GPCR autoantibodies themselves can serve as therapeutic targets to reduce patients' morbidity and mortality, representing a new area for the development of novel therapeutic interventions.
Keywords:Anti-GPCR Autoantibodies, Autoimmune Diseases, COVID-19, Post-COVID, Rheumatic Diseases, Animals, Mice
Source:Autoimmunity Reviews
Page Range:103310
Date:May 2023
Official Publication:https://doi.org/10.1016/j.autrev.2023.103310
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library